The 2-Deoxyglucose Test as a Supplement to Fasting for Detection of Childhood Hypoglycemia

Abstract

Summaryhvvodvcemic, it is inevitably dificult and not without risk.The acute response to simulated hypoglycemia induced by 2-deoxyglucose (2DG) was compared with the prolonged fasting test as a possible screening test for detection of childhood hypoglycemia. Ten children, ages 2-9 yr, without a documented history of hypoglycemia were classified retrospectively as reference subjects. While fasting, their plasma glucose decreased to an average of 50 mg/dl (range, 30-74) between 28-36 h. After infusion of 2DG, 50 mg/kg IV over 30 min, their plasma glucose increased by an average of 35 mg/dl (range, 19-56) between 60-120 min. The half-life of plasma 2DG was 48 min.Twenty-three other children in the same age range had an abnormal response to one or both of these tests. Thirteen of these children became definitely hypoglycemic while fasting (glucose < 30 mg/dl) and also failed to increase their plasma glucose by more than 10 mg/dl after 2DG. Five children had plasma glucose values between 30-40 mg/dl during the first 24 h of fasting that were associated with a change in mental status but responded to 2DC with an increase in plasma glucose. The remaining five subjects had an apparently normal response to fasting but did not respond to 2DG; two of these had documented spontaneous hypoglycemia. No cases of documented hypoglycemia were undetected by either test. It is concluded that the 2DG test is a short safe supplement to fasting which is equally effective as the prolonged fasting test in detecting hypoglycemia. Neither test alone is completely reliable, but the combination is complementary. Abbreviation

Glycolytic interference blocks influenza A virus propagation by impairing viral polymerase-driven synthesis of genomic vRNA

“…As studies in which a virus infection was more successfully treated in humans through metabolic interference, these clinical trials may become a milestone in the development of host-targeted metabolic drugs as antivirals. However, some studies [87, 88] and its poor pharmacokinetic properties, e.g., its short plasma half-life [89], suggest that 2-DG itself may never become a licensed drug. Nevertheless, it is a useful tool to examine the principles of glycolytic interference and novel 2-DG analogs or other glycolytic inhibitors possibly boast a better pharmacological suitability [90].…”

Metabolic reprogramming as a novel therapeutic target for Coxsackievirus B3

“…Based on these data, 2-DG could be suggested as a more effective anti-CVB3 agent than SO, but should be very cautious in claims. 2-DG has poor pharmacokinetic properties, such as short half-life, making it a relatively inferior as a therapeutic agent (Hansen et al 1984 ). Moreover, in order to compete with blood glucose, 2-DG should be administered at a high concentration (Strandberg et al 2013 ).…”